| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/22/2014 | CN103533955A Method for priming of t cells |
| 01/22/2014 | CN103533954A Combination vaccines with lower doses of antigen and/or adjuvant |
| 01/22/2014 | CN103533953A Vaccine against streptococcus pneumoniae |
| 01/22/2014 | CN103533943A Prevention of adverse effects caused by cd3 specific binding domains |
| 01/22/2014 | CN103533935A Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses |
| 01/22/2014 | CN103525941A Application of CTHRC1 genes in preparation of drugs for detecting/treating cervical cancer |
| 01/22/2014 | CN103525855A Method for preparing recombinant enterovirus 71 type virus-like particle |
| 01/22/2014 | CN103525777A VII type Newcastle disease virus L-gene mutation attenuated vaccine strain and preparation method thereof |
| 01/22/2014 | CN103525775A Free receptor recombinant adenovirus group for expressing porcine reproductive and respiratory syndrome virus (PRRSV), and preparation and application thereof |
| 01/22/2014 | CN103525773A Method for improving porcine reproductive and respiratory syndrome virus target cell infection titer and application of method |
| 01/22/2014 | CN103525772A Strain of duck viral hepatitis virus and application thereof |
| 01/22/2014 | CN103525771A Goose parvovirus and applications thereof |
| 01/22/2014 | CN103525770A Application of human fetal lung fibroblast line in preparation of hepatitis A vaccines |
| 01/22/2014 | CN103524624A Newcastle disease virus and duck circovirus fusion protein as well as coding gene and application thereof |
| 01/22/2014 | CN103524621A Anti-human CD20 chimeric monoclonal antibody |
| 01/22/2014 | CN103524620A Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
| 01/22/2014 | CN103524619A Antibodies directed to avss6 and uses thereof |
| 01/22/2014 | CN103524618A 促红细胞生成素受体结合抗体 Erythropoietin receptor binding antibody |
| 01/22/2014 | CN103524601A Epitope peptide in human spawn ZP (zona pellucida) protein 4 and application of epitope peptide |
| 01/22/2014 | CN103520737A Carbon nano tube carrier vaccination-free vaccine as well as preparation method and application thereof in preparation of aquatic immune offspring seed |
| 01/22/2014 | CN103520724A Novel application of inhibitor for protein HSD17B13 or coding genes thereof |
| 01/22/2014 | CN103520719A Buccal antibody product and preparation method for same |
| 01/22/2014 | CN103520718A Drug for treating liver cancer and application of RACO-1 monoclonal antibody |
| 01/22/2014 | CN103520717A Application of alanine serving as vaccine adjuvant |
| 01/22/2014 | CN103520716A Preparation method for avian influenza virus split vaccine |
| 01/22/2014 | CN103520715A Method for producing porcine circovirus II type inactivated vaccine by utilizing WAVE bioreactor |
| 01/22/2014 | CN103520714A Coccidiosis trivalent live vaccine and preparation method and application thereof |
| 01/22/2014 | CN103520713A Recombinant vaccine of ApoB100 yeast as well as preparation method and application thereof |
| 01/22/2014 | CN103520712A Tissue-factor-based tumor peptide vaccine as well as preparation method and application thereof |
| 01/22/2014 | CN103520219A Nature immunologic adjuvant and vaccine composition thereof, as well as preparation method |
| 01/22/2014 | CN103520198A Method for preventing tumor-induced T cell aging and reversing immunosuppression capability of tumor-induced T cell, and use of tumor-induced T cell in antitumor immunological therapy |
| 01/22/2014 | CN103520105A Oral encapsulated preparation for aquatic animals, process for the preparation of same, and usage of same |
| 01/22/2014 | CN102935226B Typhoid fever and paratyphoid fever combined vaccine and preparation method thereof |
| 01/22/2014 | CN102382179B Peptide sequences and compositions |
| 01/22/2014 | CN102026634B Induction of tumor hypoxia for cancer therapy |
| 01/22/2014 | CN101903043B Modified influenza virus |
| 01/21/2014 | US8633305 Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules |
| 01/21/2014 | US8633301 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| 01/21/2014 | US8633170 Therapy-enhancing glucan |
| 01/21/2014 | US8632984 RBM3 as a marker for malignant melanoma prognosis |
| 01/21/2014 | US8632801 Stable therapeutic formulations |
| 01/21/2014 | US8632785 Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| 01/21/2014 | US8632784 Nucleic acids and proteins from Streptococcus pneumoniae |
| 01/21/2014 | US8632783 Compositions for immunising against Staphylococcus aureus |
| 01/21/2014 | US8632782 Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region |
| 01/21/2014 | US8632781 Immunogenic compounds comprising peptides of IL1β |
| 01/21/2014 | US8632780 Human complement C3 derivates with cobra venom factor-like function |
| 01/21/2014 | US8632779 S. aureus polypeptides and antibodies |
| 01/21/2014 | US8632778 Stabilized anti-interleukin-6 antibody-containing preparations |
| 01/21/2014 | US8632776 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies |
| 01/21/2014 | US8632775 Apoptotic anti-IgE antibodies |
| 01/21/2014 | US8632774 Antagonists of IL-6 |
| 01/21/2014 | US8632773 Antibody composition with altered Fab sialylation |
| 01/21/2014 | US8632772 Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| 01/21/2014 | DE202012012768U1 Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen Aluminum compounds for use in therapeutics and vaccines |
| 01/21/2014 | CA2722600C Anti-hepcidin antibodies and methods of use |
| 01/21/2014 | CA2673373C Rsv f-protein and its use |
| 01/21/2014 | CA2665748C Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 01/21/2014 | CA2638757C Chimeric adenoviral vectors |
| 01/21/2014 | CA2604034C Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| 01/21/2014 | CA2561405C Monoclonal antibodies to gastrin hormone |
| 01/21/2014 | CA2559144C Estrogen receptor alpha splice variant er-.alpha.36 |
| 01/21/2014 | CA2478047C Rs7 antibodies |
| 01/21/2014 | CA2446723C Antibodies that immunospecifically bind to trail receptors |
| 01/21/2014 | CA2427257C Expression vectors able to elicit improved immune response and methods of using same |
| 01/21/2014 | CA2418014C Immunotherapy for chronic myelocytic leukemia |
| 01/21/2014 | CA2414374C Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/21/2014 | CA2388477C Recombinant gelatins with uniform molecular weight |
| 01/21/2014 | CA2378437C Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 01/21/2014 | CA2341763C Antigenic peptides of aglyco 10b and antibodies thereto |
| 01/16/2014 | WO2014012090A1 Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
| 01/16/2014 | WO2014012007A2 Rspo3 binding agents and uses thereof |
| 01/16/2014 | WO2014011984A1 Toxicity management for anti-tumor activity of cars |
| 01/16/2014 | WO2014011829A1 Protein complex system for increased immunogenicity and functionality, and methods making and use |
| 01/16/2014 | WO2014011645A1 Protective vaccine based on staphylococcus aureus sa2493 protein |
| 01/16/2014 | WO2014011489A2 Monoclonal antibodies for use in diagnosis and therapy of cancers and automimmune disease |
| 01/16/2014 | WO2014011465A2 Aptamer-targeted antigen delivery |
| 01/16/2014 | WO2014011274A2 Metalloproteinase-9 oligopeptides and their therapeutic use |
| 01/16/2014 | WO2014011072A1 Producer of newcastle disease virus strain ndv/anas crecca/omsk/9/2010 usable for producing a candidate anti-cancer preparation on the basis thereof |
| 01/16/2014 | WO2014010890A1 An antibody composition for prevention or treatment of mutant hepatitis b virus infection |
| 01/16/2014 | WO2014010758A1 Anti-tumour agent, marker for tumour detection, and oral vaccine agent |
| 01/16/2014 | WO2014010718A1 Chiral nucleic acid adjuvant |
| 01/16/2014 | WO2014010586A1 Pharmaceutical preparation for injection |
| 01/16/2014 | WO2014010232A1 Ly6k epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010231A1 Kif20a epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010229A1 Cdca1 epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014009438A2 Mycobacterial antigen vaccine |
| 01/16/2014 | WO2014009433A1 Mycobacterium resuscitation promoting factor for use as adjuvant |
| 01/16/2014 | WO2014009209A2 Immunoregulatory vaccine |
| 01/16/2014 | WO2013168965A3 Vaccine composition for preventing staphylococcus aureus infection |
| 01/16/2014 | WO2013167842A3 Immunogenic composition comprising a peptide derived from vegf and uses of same |
| 01/16/2014 | WO2013165982A3 Anti-human cytomegalvirus antibodies and use thereof |
| 01/16/2014 | WO2013093629A3 Modular vaccines, methods and compositions related thereto |
| 01/16/2014 | US20140017774 Pca3, pca3 genes, and methods of use |
| 01/16/2014 | US20140017322 Supramolecular functionalization of graphitic nanoparticles for drug delivery |
| 01/16/2014 | US20140017313 Formulations |
| 01/16/2014 | US20140017279 Adjuvant nanoemulsions with crystallisation inhibitors |
| 01/16/2014 | US20140017274 Method for the production of protein complexes and vaccine compositions comprising the same |
| 01/16/2014 | US20140017273 Albumin-Fused Anti-Angiogenesis Peptides |
| 01/16/2014 | US20140017272 Transgenic algae for delivering antigens to an animal |